Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy
Authors
Keywords
-
Journal
Communications Biology
Volume 4, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-25
DOI
10.1038/s42003-020-01631-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A mathematical model for nanomedicine pharmacokinetics and tumor delivery
- (2020) Prashant Dogra et al. Computational and Structural Biotechnology Journal
- Image‐guided mathematical modeling for pharmacological evaluation of nanomaterials and monoclonal antibodies
- (2020) Prashant Dogra et al. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- Dendrimers towards translational nanotherapeutics: Concise key step analysis
- (2020) Jean Pierre Majoral et al. BIOCONJUGATE CHEMISTRY
- AZD4320, a dual inhibitor of Bcl-2 and Bcl-xL, induces tumor regression in hematological cancer models without dose-limiting thrombocytopenia
- (2020) Srividya B Balachander et al. CLINICAL CANCER RESEARCH
- Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: “Drug Products, Including Biological Products, that Contain Nanomaterials”
- (2019) Jon S. B. de Vlieger et al. AAPS Journal
- Mathematical modeling in cancer nanomedicine: a review
- (2019) Prashant Dogra et al. BIOMEDICAL MICRODEVICES
- Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension
- (2018) Teresa Collins et al. BRITISH JOURNAL OF PHARMACOLOGY
- Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics
- (2018) Prashant Dogra et al. Nature Communications
- Mass spectrometry imaging of the in situ drug release from nanocarriers
- (2018) Jinjuan Xue et al. Science Advances
- Tumour regression and improved gastrointestinal tolerability from controlled release of SN-38 from novel polyoxazoline-modified dendrimers
- (2017) Richard M. England et al. JOURNAL OF CONTROLLED RELEASE
- Comprehensive study of the drug delivery properties of poly( l -lactide)-poly(ethylene glycol) nanoparticles in rats and tumor-bearing mice
- (2017) Vladimir Shalgunov et al. JOURNAL OF CONTROLLED RELEASE
- Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles
- (2017) Nicolas Floc'h et al. MOLECULAR CANCER THERAPEUTICS
- Overview of the Use of Murine Models in Leukemia and Lymphoma Research
- (2017) Rebecca Kohnken et al. Frontiers in Oncology
- Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
- (2016) Susan Ashton et al. Science Translational Medicine
- A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins
- (2015) Katherine L. Gill et al. AAPS Journal
- Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity
- (2015) Hiroshi Maeda ADVANCED DRUG DELIVERY REVIEWS
- Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: A concise overview
- (2013) Serge Mignani et al. ADVANCED DRUG DELIVERY REVIEWS
- Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
- (2013) U. Prabhakar et al. CANCER RESEARCH
- A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions
- (2013) Lorna Ewart et al. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS
- Animal welfare and the 3Rs in European biomedical research
- (2011) Dominic J. Wells Annals of the New York Academy of Sciences
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties
- (2011) Lisa M Kaminskas et al. Nanomedicine
- Physiologically Based Pharmacokinetic Modeling of Nanoparticles
- (2010) Mingguang Li et al. ACS Nano
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- The Impact of Molecular Weight and PEG Chain Length on the Systemic Pharmacokinetics of PEGylated Polyl-Lysine Dendrimers
- (2008) Lisa M. Kaminskas et al. MOLECULAR PHARMACEUTICS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started